<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) is the most common form of <z:hpo ids='HP_0000726'>dementia</z:hpo>, and is characterized by a degeneration of neurones and their synapses, and a higher number of <z:hpo ids='HP_0100256'>senile plaques</z:hpo> (SP) and <z:hpo ids='HP_0002185'>neurofibrillary tangles</z:hpo> (NFT) compared with that found in non-<z:e sem="disease" ids="C0860630" disease_type="Mental or Behavioral Dysfunction" abbrv="">demented</z:e> individuals of the same age </plain></SENT>
<SENT sid="1" pm="."><plain>NFT are composed of a hyperphosphorylated and ubiquitinated form of tau protein </plain></SENT>
<SENT sid="2" pm="."><plain>Previous studies have found that in the cerebrospinal fluid (CSF) both tau and ubiquitin are increased in AD </plain></SENT>
<SENT sid="3" pm="."><plain>We examined CSF-tau and CSF-ubiquitin in a population based sample of 85-year-olds, 26 demented (11 with probable <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD), 13 with probable vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VAD) and 2 with mixed (AD/VAD) type of <z:hpo ids='HP_0000726'>dementia</z:hpo>) and 35 non-<z:e sem="disease" ids="C0860630" disease_type="Mental or Behavioral Dysfunction" abbrv="">demented</z:e> individuals </plain></SENT>
<SENT sid="4" pm="."><plain>CSF-tau was significantly higher both in the probable AD group (254 +/- 113 pg/mL; P &lt; 0.01), and in the probable VAD group (247 +/- 75 pg/mL; P &lt; 0.005), than in the non-<z:e sem="disease" ids="C0860630" disease_type="Mental or Behavioral Dysfunction" abbrv="">demented</z:e> group (171 +/- 78 pg/mL), but did not significantly differ between the probable AD and probable VAD groups </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, CSF-ubiquitin did not significantly differ between the probable AD (100 +/- 24 ng/mL), probable VAD (102 +/- 16 ng/mL), and non-<z:e sem="disease" ids="C0860630" disease_type="Mental or Behavioral Dysfunction" abbrv="">demented</z:e> (97 +/- 27 ng/mL) groups </plain></SENT>
<SENT sid="6" pm="."><plain>CSF-tau increased with increasing severity of <z:hpo ids='HP_0000726'>dementia</z:hpo> (P &lt; 0.001), though no such relation was found for CSF-ubiquitin </plain></SENT>
<SENT sid="7" pm="."><plain>Neither CSF-tau nor CSF-ubiquitin differed between patients with or without the <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> E E4 isoform </plain></SENT>
<SENT sid="8" pm="."><plain>Higher CSF-tau and CSF-ubiquitin levels were also associated with increasing degree of cortical and central brain <z:mpath ids='MPATH_127'>atrophy</z:mpath> as measured by computerized tomography </plain></SENT>
<SENT sid="9" pm="."><plain>The relationships between CSF-tau and severity of <z:hpo ids='HP_0000726'>dementia</z:hpo> and to brain <z:mpath ids='MPATH_127'>atrophy</z:mpath> suggest that CSF-tau may be used as a measure of neuronal/<z:mp ids='MP_0005405'>axonal degeneration</z:mp> in patients with <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>We have previously shown a marked increase in both CSF-tau and CSF-ubiquitin in younger patients with AD and VAD </plain></SENT>
<SENT sid="11" pm="."><plain>The less pronounced increase in CSF-tau and the lack of difference in CSF-ubiquitin in older patients suggest that the severity of the degenerative process is less in older than in younger <z:e sem="disease" ids="C0860630" disease_type="Mental or Behavioral Dysfunction" abbrv="">demented</z:e> patients </plain></SENT>
</text></document>